Welcome to our dedicated page for Omnicell Com SEC filings (Ticker: OMCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omnicell, Inc. (NASDAQ: OMCL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. As a publicly traded healthcare technology company focused on intelligent medication management, Omnicell files a range of reports with the U.S. Securities and Exchange Commission that describe its financial condition, risks, governance, and material events.
Investors and researchers can use this page to review Omnicell’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss topics such as revenues from connected devices, technical services, SaaS and Expert Services, and consumables, as well as the company’s strategy to transform into a digitally enabled medication management technology company. Current reports on Form 8-K provide timely updates on matters including quarterly financial results, amendments to bylaws, and the appointment of executive officers.
For users interested in governance and corporate structure, filings detail actions like the adoption of amended and restated bylaws that refine stockholder nomination procedures, address proxy rule requirements, and clarify jurisdictional provisions. Risk factor discussions in Omnicell’s periodic reports outline considerations related to economic conditions, demand for medication management solutions, regulatory and legal obligations, cybersecurity, supply chain, and competition.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the implications of Omnicell’s 10-Ks, 10-Qs, and 8-Ks without reading every page. Real-time updates from EDGAR, combined with structured access to historical filings, allow investors to follow how OMCL’s disclosures evolve over time and to connect regulatory information with the company’s broader narrative in medication management technology.
Omnicell, Inc. reported stronger results for the three months ended March 31, 2026, with total revenues of $309.9 million compared to $269.7 million a year earlier, driven by growth in both product and service revenues. Net income was $11.4 million, versus a net loss of $7.0 million in the prior-year period, and diluted earnings per share reached $0.25.
Operating cash flow increased to $54.5 million from $25.9 million, supporting a cash, cash equivalents, and restricted cash balance of $291.0 million and total assets of $2.0 billion. The company ended the quarter with no borrowings under its $350.0 million revolving credit facility and had $172.5 million of 1.00% Convertible Senior Notes due 2029 outstanding.
Omnicell Inc ownership disclosed: Vanguard Capital Management reports beneficial ownership of 2,274,766 shares of Omnicell common stock, representing 5% of the class. The filing shows Vanguard has sole voting power for 340,249 shares and sole dispositive power for 2,274,766 shares. The Schedule 13G is signed by Ashley Grim on 04/30/2026.
Vanguard Portfolio Management reports beneficial ownership of 3,240,874 shares of Omnicell Inc common stock, representing 7.13% of the class as of 03/31/2026. The filing shows sole voting power over 26,108 shares and sole dispositive power over 3,240,874 shares; transactions and holdings are reported on Schedule 13G and the filing is signed on 04/29/2026.
Omnicell, Inc. reported a strong first quarter of 2026, with total revenues of $309.9 million, up 15% from the first quarter of 2025, driven by connected devices, technical services, SaaS and Expert Services, and consumables. GAAP results improved from a prior-year loss to net income of $11.4 million, or $0.25 per diluted share, while non-GAAP net income rose to $25.0 million, or $0.55 per diluted share. Non-GAAP EBITDA increased to $44.7 million, reflecting better profitability and cost discipline. The company generated $54.5 million of operating cash flow and ended March 31, 2026 with $239.2 million in cash and cash equivalents and $167.9 million of convertible senior notes. Omnicell raised its full year 2026 guidance for non-GAAP EBITDA to $153–$168 million and non-GAAP EPS to $1.80–$2.00, and now expects 2026 total revenues of $1.215–$1.255 billion.
Omnicell, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 19, 2026. Holders of 45,477,299 common shares as of March 27, 2026 may vote online or by proxy.
Stockholders will elect three Class I directors to serve until the 2029 annual meeting, cast an advisory say‑on‑pay vote on named executive officer compensation, and consider an amendment to the 2009 Equity Incentive Plan to add 1,600,000 shares for future equity awards. They will also vote on amending the Amended and Restated Certificate of Incorporation to add Delaware‑permitted officer exculpation and make minor updates, and on ratifying Deloitte & Touche LLP as independent auditor for 2026.
The nine‑member, largely independent board uses a combined CEO/Chairman structure with a Lead Independent Director, formal risk oversight (including cybersecurity), stock ownership guidelines, anti‑hedging and insider‑trading policies, and standing Audit, Compensation, Corporate Governance, and M&A committees. Non‑employee directors receive cash retainers and annual restricted stock awards for board and committee service.
Njoku Nnamdi reported acquisition or exercise transactions in this Form 4 filing.
OMNICELL, INC. Executive Vice President and Chief Operating Officer Nnamdi Njoku received a grant of 46,296 shares of common stock in the form of Restricted Stock Units as equity compensation. The award was granted under the company’s equity incentive plan at no cash cost to him.
One-third of these RSUs will vest on the first anniversary of the April 1, 2026 grant date. The remaining two-thirds will vest in equal installments on the second and third anniversaries. After this grant, Njoku directly holds 161,535.4457 shares of Omnicell common stock.
Manley Corey J reported acquisition or exercise transactions in this Form 4 filing.
OMNICELL, INC. executive Corey J. Manley, EVP & Chief Legal/Admin Officer, received a grant of 25,132 Restricted Stock Units (RSUs) of common stock at a stated price of $0.00 per share, reflecting a compensation-related equity award rather than a market purchase.
According to the award terms, one-third of the RSUs will vest on the first anniversary of the grant date, with the remaining two-thirds vesting in equal installments on the second and third anniversaries. Following this grant, Manley directly holds a total of 121,849.3392 shares of Omnicell common stock, including this new RSU award.
LIPPS RANDALL A reported acquisition or exercise transactions in this Form 4 filing.
OMNICELL, INC. Chairman, President and CEO Randall A. Lipps received a grant of 90,939 shares of Common Stock in the form of restricted stock units at a price of $0.00 per share on 2026-04-01. These RSUs were granted under the company’s equity incentive plan.
According to the vesting schedule, one-third of the RSUs will vest on the first anniversary of the grant date, with the remaining two-thirds vesting in equal installments on the second and third anniversaries. After this grant, Lipps directly holds 535,531.0741 shares of Common Stock.
In addition to his direct holdings, shares are also held indirectly in trusts: 355,861 shares are held in trust with his wife, and 8,051 shares are held in trust for the benefit of his children.
Radford Harlan Baird reported acquisition or exercise transactions in this Form 4 filing.
OMNICELL, INC. reported that EVP & Chief Financial Officer Harlan Baird Radford received a grant of 37,037 shares of Common Stock in the form of Restricted Stock Units under the company’s equity incentive plan. One-third of the RSUs will vest on the first anniversary of the grant date, with the remaining two-thirds vesting in equal installments on the second and third anniversaries. Following this award, Radford directly holds 69,969 shares of Common Stock.